
CARsgen Therapeutics Holdings Ltd
HKEX:2171

Gross Margin
CARsgen Therapeutics Holdings Ltd
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Gross Margin Across Competitors
Country | Company | Market Cap |
Gross Margin |
||
---|---|---|---|---|---|
CN |
![]() |
CARsgen Therapeutics Holdings Ltd
HKEX:2171
|
8.7B HKD |
37%
|
|
FR |
![]() |
Pharnext SCA
OTC:PNEXF
|
6T USD |
0%
|
|
US |
![]() |
Abbvie Inc
NYSE:ABBV
|
336.8B USD |
70%
|
|
US |
![]() |
Amgen Inc
NASDAQ:AMGN
|
150.9B USD |
62%
|
|
US |
![]() |
Gilead Sciences Inc
NASDAQ:GILD
|
131B USD |
78%
|
|
US |
![]() |
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
126B USD |
86%
|
|
US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
76%
|
|
AU |
![]() |
CSL Ltd
ASX:CSL
|
118.3B AUD |
52%
|
|
US |
![]() |
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
66.1B USD |
87%
|
|
US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
75%
|
|
NL |
![]() |
argenx SE
XBRU:ARGX
|
32.7B EUR |
90%
|
CARsgen Therapeutics Holdings Ltd
Glance View
CARsgen Therapeutics Holdings Ltd. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of CAR-T cell therapies. The company is headquartered in Shanghai, Shanghai and currently employs 573 full-time employees. The company went IPO on 2021-06-18. The Company’s therapies are applied in the treatment of hematological malignancies and solid tumors. The firm have developed an upgraded B cell maturation antigen (BCMA) targeted CAR-T product, CT053, which is its sole core product candidate. The firm conducts its businesses in China and the United States.

See Also
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Based on CARsgen Therapeutics Holdings Ltd's most recent financial statements, the company has Gross Margin of 37.4%.